SCHEMBL6000218

SCHEMBL6000218

CN(c1ccncc1)c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.46
CHRM5 P08912 1/20 0.43
CHKA P35790 1/20 0.43
GRM1 Q13255 1/20 0.40
CYP17A1 P05093 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
TAAR1 Q96RJ0 2/20 0.38
KDM4C Q9H3R0 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ACHE P22303 1/20 0.38
KDM6B O15054 1/20 0.38
TP53 P04637 1/20 0.37
LRRK2 Q5S007 1/20 0.36
NFE2L2 Q16236 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12774528 0.84 ABCG2 (0.54) ABCG2CHKATAAR1NPC1RAB9A
SCHEMBL13367477 0.79 KDM4C (0.46) CHRM5CHKAKDM4CKMT2AACHE
SCHEMBL17504172 0.79 MTOR (0.42) ABCG2KDM4CNPC1RAB9AKMT2A
SCHEMBL13338178 0.78 ABL1 (0.46) ABCG2CYP3A4CYP11B1CYP11B2NPC1
SCHEMBL5998627 0.78 CHRM5 (0.52) CHRM5CHKAGRM1TAAR1NPC1
SCHEMBL5998795 0.78 GRM5 (0.45) CHRM5CHKACYP11B1CYP11B2TAAR1
SCHEMBL6000283 0.78 GRM4 (0.48) CHRM5CHKATAAR1KDM4CKMT2A
SCHEMBL2223507 0.78 CHKA (0.56) CHRM5CHKACYP3A4KMT2ASLC6A2
SCHEMBL3409151 0.77 CHRM5 (0.68) CHRM5CHKANPC1RAB9AKMT2A
SCHEMBL10621182 0.76 CHRM5 (0.42) CHRM5CHKAACHESLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C ABCG2 2614/4885CHRM5 96/4885CHKA 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.